Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One Down, But More Remain: PDL Settles Patent Scrap With Alexion Over Soliris

This article was originally published in The Pink Sheet Daily

Executive Summary

One-time $25M payout for license ends dispute over royalties for hemoglobinuria therapy.

You may also be interested in...

PDL Stockholders Get $500 Million, As Promised

Troubled biotech spins off R&D, leaves shell to manage royalty income.

AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune

Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.

Alexion Biologic Soliris Is First To Get FDA Nod For Rare Blood Disease

Soliris is slated to launch within two weeks from its March 16 approval.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts